PAVmed restructures capital to back EsoGuard commercialization

PAVmed restructures capital to back EsoGuard commercialization

PAVmed Inc. is closing a financing and capital restructuring designed to remove legacy convertible instruments and better support commercialization of the EsoGuard Esophageal DNA Test marketed by its Lucid Diagnostics unit. The company issues $30 million of Series D convertible preferred stock and concurrently takes a $15 million senior secured note due February 2029, using the proceeds to redeem and retire all outstanding Series C preferred and convertible debt. Management says the move eliminates a long‑standing capital structure overhang that has constrained strategic flexibility for both PAVmed and Lucid.

Executives frame the transactions as a platform to accelerate reimbursement, market access and clinical adoption for EsoGuard, arguing that simplified capitalization reduces dilution risk and lowers near‑term refinancing needs. By removing prior convertible securities, PAVmed expects to provide clearer visibility into future equity value and a more predictable pathway for Lucid to pursue Medicare and commercial payor coverage. The company highlights that the financing comes from existing long‑term investors and is structured to advance commercialization rather than alter operating plans.

The financing is also conditional in part on regulatory and reimbursement milestones tied to EsoGuard: investors receive warrants exercisable into additional Series D shares for up to $30 million if a positive draft Medicare local coverage determination (LCD) for EsoGuard is published. PAVmed says that aligning incremental funding with reimbursement progress allows the business to scale commercialization spending if and when payor coverage prospects improve, while keeping initial dilution contained until a demonstrable market access outcome.

Shareholder approval sought for conversion plan

PAVmed schedules a special meeting of stockholders no later than April 30, 2026 to seek approval to convert the Series D preferred into common stock at a $6.50 per share conversion price. The company holds voting agreements from holders representing roughly 25% of outstanding common stock in support of the conversion proposal, which is intended to result in a capital structure comprised entirely of common equity and long‑term debt upon approval and any warrant exercise.

Near‑term cash and contingent upside

Combined financings generate a $22.3 million cash payment used alongside the $15 million note to retire prior securities, leaving about $7.7 million of net cash for working capital and materially strengthening the balance sheet. PAVmed notes that, assuming warrant exercise following a positive EsoGuard LCD and subsequent conversion, the transactions would add about $37.7 million in cash and produce a cleaner capital structure to support Lucid’s commercialization efforts.